
    
      Study participants will receive either a single dose of SP306 vaccine intramuscularly or a
      dose of DT vaccine subcutaneously. They will be monitored after vaccination for immediate
      adverse events (AEs) solicited injection site and systemic reactions and unsolicited AEs
      including serious adverse events throughout the study period, approximately 28 days (+7
      days).
    
  